Clinical Trials Logo

Brain Metastases, Adult clinical trials

View clinical trials related to Brain Metastases, Adult.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05999357 Withdrawn - Clinical trials for Brain Metastases, Adult

JDQ443 for KRAS G12C NSCLC Brain Metastases

STRIDER
Start date: April 15, 2024
Phase: Phase 2
Study type: Interventional

The goal of this phase II clinical trial is to evaluate the intracranial efficacy of JDQ443, a KRAS G12C inhibitor in patients with KRAS G12C+ NSCLC and brain metastases (cohort A: asymptomatic, untreated brain metastases, cohort B: asymptomatic, treated brain metastases). The main question it aims to answer is to evaluate the intracranial efficacy, according to RANO-BM criteria, in patients with asymptomatic and untreated brain metastases. Participants will receive JDQ443 200 mg BID until unacceptable toxicity or disease progression.